These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 10786259

  • 1. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 15; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil: an update of its use in essential hypertension.
    Easthope SE, Jarvis B.
    Drugs; 2002 Dec 15; 62(8):1253-87. PubMed ID: 12010090
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil. A review of its use in essential hypertension.
    McClellan KJ, Goa KL.
    Drugs; 1998 Nov 15; 56(5):847-69. PubMed ID: 9829158
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 15; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 7. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
    Melian EB, Jarvis B.
    Drugs; 2002 Sep 15; 62(5):787-816. PubMed ID: 11929332
    [Abstract] [Full Text] [Related]

  • 8. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil.
    Sever PS.
    J Hypertens Suppl; 1997 Dec 15; 15(6):S9-12. PubMed ID: 9493121
    [Abstract] [Full Text] [Related]

  • 9. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S.
    Am J Hypertens; 2000 Jan 15; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [Abstract] [Full Text] [Related]

  • 10. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 15; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
    Andersson OK.
    Basic Res Cardiol; 1998 Sep 15; 93 Suppl 2():54-8. PubMed ID: 9833164
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy and tolerability of candesartan cilexetil. Candesartan Study Groups in Japan.
    Ogihara T, Arakawa K.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S27-31; discussion S33-4. PubMed ID: 10076918
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.
    McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF.
    J Hum Hypertens; 2000 Apr 15; 14(4):263-9. PubMed ID: 10805052
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
    Buter H, Navis GY, Woittiez AJ, de Zeeuw D, de Jong PE.
    Eur J Clin Pharmacol; 1999 Feb 15; 54(12):953-8. PubMed ID: 10192757
    [Abstract] [Full Text] [Related]

  • 16. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK, Neldam S.
    Blood Press; 1998 Jan 15; 7(1):53-9. PubMed ID: 9551878
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
    Azizi M, Chatellier G, Guyene TT, Ménard J.
    J Hypertens; 1999 Apr 15; 17(4):561-8. PubMed ID: 10404959
    [Abstract] [Full Text] [Related]

  • 18. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
    Sever PS.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S3-10; discussion S33-4. PubMed ID: 10076915
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Kloner RA, Weinberger M, Pool JL, Chrysant SG, Prasad R, Harris SM, Zyczynski TM, Leidy NK, Michelson EL, Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
    Am J Cardiol; 2001 Mar 15; 87(6):727-31. PubMed ID: 11249891
    [Abstract] [Full Text] [Related]

  • 20. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K, Naka T, Chatani F, Yoshimura Y.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.